The usefulness of 2-nitroimidazole-sodium borocaptate-10B conjugates as 10B-carriers in boron neutron capture therapy
The usefulness of 2-nitroimidazole-sodium borocaptate-10B conjugates as 10B-carriers in boron neutron capture therapy
复制标题
DOI:
10.1016/j.apradiso.2004.05.018
复制
发表时间:
2004-11-01
影响因子:
1.6
通讯作者:
Ono, K
中科院分区:
文献类型:
--
作者:
Masunaga, S;Nagasawa, H;Ono, K
We evaluated the usefulness of five new B-10-compounds (TX-2016, TX-2017, TX-2018, TX-2041, and TX-2042) as B-10-carriers in boron neutron capture therapy (BNCT). They are 2-nitroimidazole-sodium borocaptate-B-10 (BSH) conjugates, that is, hybrid compounds that have both hypoxic tumor cell sensitizing unit under gamma-ray irradiation, 2-nitroimidazoles, and thermal neutron-sensitizing unit, BSH. B-10 distribution analyses in tumors and blood indicated that TX-2041 has the most favorable characteristics for localizing a sufficient amount of B-10 into tumors and keeping the B-10 concentration high during neutron beam irradiation. In addition, TX-2041 showed a significantly higher radio-sensitization effect with reactor thermal neutron beams than BSH on both total (= proliferating (P) + quiescent (Q)) and hypoxia-rich Q cell populations in solid tumors. Further, TX-2041 clearly demonstrated a radio-sensitization effect with gamma-rays on both cell populations, which could never be achieved by BSH. B-10-carrier with a hypoxic tumor cell-sensitizing effect on tumors with gamma-rays as well as the potential to selectively localize and keep B-10 in tumors, such as TX-2041. are promising for use in actual BNCT. (C) 2004 Elsevier Ltd. All rights reserved.